Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
EMERGENT BIOSOLUTIONS INVESTOR ALERT: Shareholder Lawsuit Filed
02:00pm, Wednesday, 21'st Apr 2021
Boston, Massachusetts--(Newsfile Corp. - April 21, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE:
FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training
12:38pm, Wednesday, 21'st Apr 2021
The FDA concluded its inspection of Emergent BioSolutions Inc's (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped production on Monday. The agency released a couple of
FDA completes Emergent Biosolutions factory inspection, orders fixes
10:13am, Wednesday, 21'st Apr 2021
CNBC's Meg Tirrell reports on updates out of the FDA on its inspection of an Emergent Biosolutions, which recently botched 15 million doses of Covid vaccine.
NEW YORK--(BUSINESS WIRE)-- #EmergentBioSolutions--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United
NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 18, 2021 to fil
New York, New York--(Newsfile Corp. - April 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
Congressional investigation launched into Emergent BioSolutions' federal vaccine contracts
01:03pm, Tuesday, 20'th Apr 2021
Congressional investigators have requested top executives from Emergent BioSolutions to testify before the Select Subcommittee.
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
11:17am, Tuesday, 20'th Apr 2021
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
10:45pm, Monday, 19'th Apr 2021
NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are a
Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility
01:20pm, Monday, 19'th Apr 2021
Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine manufactured at its Baltimore site. T
Why Emergent BioSolutions Stock Is Tumbling Today
12:29pm, Monday, 19'th Apr 2021
The company has halted production of COVID-19 vaccines at its Baltimore facility as an FDA inspection moves forward.
Emergent BioSolutions says it has agreed with FDA not to manufacture new material at Baltimore facility
06:42am, Monday, 19'th Apr 2021
Drug contract company Emergent BioSolutions Inc. said Monday it has made an agreement with the U.S. Food and Drug Administration not to manufacture any new material at its Bayview facility in Baltimor
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
06:30am, Thursday, 15'th Apr 2021
GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial re
Why Emergent BioSolutions Stock Fell Today
03:35pm, Tuesday, 13'th Apr 2021
The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
07:05am, Tuesday, 13'th Apr 2021
NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are adv
